Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 5
Transitioning Patients Back to Community Practices Following CAR T
Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy.
EP: 1.Identifying Potential Candidates for CAR T-Cell Therapy
EP: 2.Treating Patients Referred to Academic Centers for CAR T
EP: 3.CAR T-Cell Therapy: Leukapheresis Practices
EP: 4.Triaging and Prioritizing Patients with Multiple Myeloma
Now Viewing
EP: 5.Transitioning Patients Back to Community Practices Following CAR T
EP: 6.Monitoring Adverse Events Following CAR T-Cell Therapy
- Dr. Krishnan: What criteria or thresholds do you use to determine when a patient is ready for transition back to the community oncologist after CAR-T therapy? (e.g. time since infusion, resolution of toxicities, evidence of response)
- Dr. Park: At what point in the patient's recovery course after CAR-T do you think it is ideal for their care to transition back to the community oncologist? What factors influence this timing?
- How much clinical/treatment detail from the CAR-T process at the academic center is typically provided or needed by community providers for optimal long-term monitoring and follow-up of the patient?
Related Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
